Get notified when WST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (worsened) — Plaintiffs expanded claims to include Section 20A (insider trading) and allegations about officers' stock transactions, broadening scope beyond original disclosure claims.
West Pharma Q2: Revenue +13.8% on GLP-1 demand; cyber incident cut $7M, compressed West Vantage margin 330bp
Filed July 23, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 24, 2025 · ~2 min read
Key Changes
-
high
May 2026 cyberattack exfiltrated data and encrypted systems, forcing global shutdown for containment. West Vantage lost ~$7M revenue from production downtime and gross margin fell 3.3 percentage points to 14.2%. Operations now fully recovered.
Risk Factors / MD&A: West Vantage verify on EDGAR → -
high
Securities class action expanded: amended complaint adds Section 20A (insider trading) claims and alleges violations tied to officers' stock transactions, not just public statements. Motion to dismiss briefing complete; ruling pending.
Legal Proceedings verify on EDGAR → -
high
SmartDose 3.5mL sale to AbbVie closed July 1, 2026 for ~$136M cash. Company expects $55-60M pre-tax gain in Q3 2026. Q2 SmartDose sales surged 29.2% ahead of transaction close.
MD&A / Notes: Subsequent Events view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade WST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 24, 2026 · How we verify